中国疾控中心发布了2026-2027年度流感疫苗接种指南，建议在9至10月完成接种1。专家指出，9月接种的疫苗在冬季流感高峰期仍具有保护效力1。通常流感流行季在11月份左右开始，提前接种可以留出充足时间使抗体产生和发挥作用1。
2026-2027年度我国上市的三价流感疫苗包括三价灭活疫苗和三价减毒活疫苗1。疫苗接种后产生的保护性抗体水平会随时间逐渐衰减，这也是每年需要重新接种的原因1。疫苗株的选择由世界卫生组织根据全球流感监测的主要流行亚型推荐，每年有所不同1。
关于疫苗配置的调整，从2020年3月以后，全世界发现Yamagata系没有了，已经五六年没有监测到1。基于这一情况，世界卫生组织建议没有必要继续生产四价疫苗，三价疫苗的性价比更高1。中国疾控中心建议所有6月龄及以上且无接种禁忌的人都应接种流感疫苗1。
China's Center for Disease Control and Prevention has released the influenza vaccination guidelines for the 2026-2027 season, recommending that immunization be completed between September and October.1 According to expert interpretation, vaccines administered in September maintain protective efficacy during the winter influenza peak, which typically begins around November.1 Early vaccination is necessary to allow sufficient time for the immune system to produce protective antibodies before the high-risk period arrives.1
The 2026-2027 influenza vaccines available in China include both inactivated and live attenuated trivalent formulations.1 The specific vaccine strains are selected annually by the World Health Organization based on global influenza surveillance data tracking major circulating subtypes, which means the composition varies from year to year.1 This annual variation necessitates yearly revaccination to maintain protection against the current season's dominant strains.1 Additionally, antibody levels generated following vaccination gradually decline over time, underscoring the importance of timely immunization each season.1
The shift to trivalent vaccines reflects evolving epidemiological data: since March 2020, the Yamagata lineage has not been detected globally, with no cases identified for five to six years.1 Consequently, the World Health Organization determined that quadrivalent vaccines are no longer necessary, and trivalent formulations offer superior cost-effectiveness.1 Health authorities recommend that all individuals aged six months and older with no contraindications receive annual influenza vaccination.1
评论
还没有评论，欢迎留下第一条。